loading
전일 마감가:
$1.72
열려 있는:
$1.73
하루 거래량:
1.11M
Relative Volume:
0.93
시가총액:
$123.04M
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
-0.6196
EPS:
-2.8
순현금흐름:
$-167.04M
1주 성능:
-11.93%
1개월 성능:
-27.41%
6개월 성능:
-63.40%
1년 성능:
-25.54%
1일 변동 폭
Value
$1.67
$1.77
1주일 범위
Value
$1.67
$2.00
52주 변동 폭
Value
$1.67
$11.48

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
명칭
Ventyx Biosciences Inc
Name
전화
(858) 945-2393
Name
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
직원
75
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
VTYX's Discussions on Twitter

VTYX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
VTYX 1.735 123.04M 0 -192.96M -167.04M -2.80
VRTX 449.80 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.38 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.88 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.15 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.49 24.89B 3.30B -501.07M 1.03B 11.54

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-06-14 재개 Credit Suisse Outperform
2023-03-21 개시 Wells Fargo Overweight
2022-12-19 개시 Goldman Buy
2022-11-17 개시 Morgan Stanley Overweight
2022-09-07 개시 Stifel Buy
2022-09-01 개시 H.C. Wainwright Buy
2022-05-09 개시 Credit Suisse Outperform
2022-03-31 개시 Canaccord Genuity Buy
2022-02-01 개시 Oppenheimer Outperform
2021-11-15 개시 Jefferies Buy
2021-11-15 개시 Piper Sandler Overweight
모두보기

Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스

pulisher
Nov 20, 2024

Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com

Nov 20, 2024
pulisher
Nov 19, 2024

Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia

Nov 19, 2024
pulisher
Nov 17, 2024

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance

Nov 17, 2024
pulisher
Nov 14, 2024

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St

Nov 14, 2024
pulisher
Nov 12, 2024

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times

Nov 12, 2024
pulisher
Nov 11, 2024

Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World

Nov 11, 2024
pulisher
Nov 08, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times

Nov 07, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha

Nov 04, 2024
pulisher
Nov 01, 2024

Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com

Nov 01, 2024
pulisher
Oct 28, 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider

Oct 28, 2024
pulisher
Oct 28, 2024

Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat

Oct 28, 2024
pulisher
Oct 17, 2024

HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 08, 2024

Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

An analyst sees good growth prospects for Ventyx Biosciences Inc (VTYX) - SETE News

Oct 07, 2024
pulisher
Oct 07, 2024

Sanofi Invests $27M in Ventyx Bio - San Diego Business Journal

Oct 07, 2024
pulisher
Oct 03, 2024

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Ventyx Biosciences Inc (VTYX) may enjoy gains as insiders got busy in the recent days - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Is Ventyx Biosciences Inc (VTYX) a good investment opportunity? - US Post News

Oct 02, 2024
pulisher
Sep 30, 2024

Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News

Sep 30, 2024
pulisher
Sep 28, 2024

VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN

Sep 28, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex

Sep 26, 2024
pulisher
Sep 26, 2024

Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle

Sep 26, 2024
pulisher
Sep 25, 2024

Adversity is less terrifying than hope: Ventyx Biosciences Inc (VTYX) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

Ventyx Biosciences retains stock target, neutral rating despite Sanofi's $27M stake - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury

Sep 24, 2024
pulisher
Sep 23, 2024

Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology

Sep 23, 2024
pulisher
Sep 23, 2024

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences - MSN

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx Biosciences Inc (VTYX) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx stock climbs 8% on $27M Sanofi investment - MSN

Sep 23, 2024
pulisher
Sep 23, 2024

Thoughtworks (NASDAQ:TWKS) Sees Large Volume Increase - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

VTYX’s Q2 earnings predictions: What the experts say - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright - TipRanks

Sep 23, 2024

Ventyx Biosciences Inc (VTYX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Ventyx Biosciences Inc 주식 (VTYX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Krueger Christopher W
CHIEF BUSINESS OFFICER
Apr 02 '24
Sale
5.40
1,651
8,921
284,999
Nuss John
CHIEF SCIENTIFIC OFFICER
Apr 02 '24
Sale
5.40
1,651
8,921
264,998
Mohan Raju
CEO AND PRESIDENT
Apr 02 '24
Sale
5.40
4,312
23,299
1,578,250
Auster Martin
CHIEF FINANCIAL OFFICER
Apr 02 '24
Sale
5.40
1,405
7,592
24,303
Krueger Christopher W
CHIEF BUSINESS OFFICER
Mar 28 '24
Option Exercise
0.00
4,531
0
286,650
Auster Martin
CHIEF FINANCIAL OFFICER
Mar 28 '24
Option Exercise
0.00
4,531
0
25,708
Mohan Raju
CEO AND PRESIDENT
Mar 28 '24
Option Exercise
0.00
11,843
0
1,582,562
Nuss John
CHIEF SCIENTIFIC OFFICER
Mar 28 '24
Option Exercise
0.00
4,531
0
266,649
Nuss John
Chief Scientific Officer
Dec 20 '23
Sale
2.12
17,628
37,334
262,118
Krueger Christopher W
Chief Business Officer
Dec 20 '23
Sale
2.12
5,293
11,210
282,119
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):